A drug that can treat chemotherapy-resistant ovarian cancer has just been approved for use on the NHS in England. Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
In the UK, over 7,500 women are diagnosed with ovarian cancer every year. By 2040, it’s predicted this number will rise to 9,400.
